This bill prohibits the Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA) from treating pregnancy as an illness when approving or regulating abortion drugs. It specifically bans using this framework for approvals under the Federal Food, Drug, and Cosmetic Act or for risk management strategies. The bill also nullifies existing approvals of abortion drugs (like mifepristone) that relied on treating pregnancy as an illness. This directly affects how the FDA regulates abortion medications, changing the basis for their safety and efficacy evaluations.
HR 6682, the Endometriosis CARE Act, requires federal agencies to advance research, improve treatment access, and increase awareness for people with endometriosis - a chronic condition causing pelvic pain and fertility challenges affecting an estimated 10% of reproductive-age individuals. The bill mandates $50 million annually for NIH research on endometriosis treatments and cures, directs HHS to analyze barriers like insurance coverage and provider shortages in accessing care, and funds public education campaigns targeting underserved racial, ethnic, and minority groups. It also requires HHS to develop provider training materials on diagnosis and care, and to commission a National Academies study on disparities in endometriosis treatment across race, geography, and insurance status. The legislation focuses on data collection, education, and research rather than altering existing insurance coverage or treatment protocols.
HR 3749, the HER Act, directs the U.S. Department of Health and Human Services to fund research on how endocrine-disrupting chemicals (chemicals that interfere with hormones) in personal care products affect women’s reproductive health. It provides federal grants for scientific research and requires states to receive funding for investigating these chemicals and running public awareness campaigns about safer alternatives. Every five years, the Department must publish reports detailing research findings, listing safe/harmful products, and suggesting ways to expand FDA regulation of harmful ingredients. This bill directly affects women’s health researchers, state health agencies, and consumers seeking safer personal care products, while aiming to inform future regulatory action.
This bill, HR 3916 (My Body, My Data Act of 2025), requires businesses and other "regulated entities" to minimize collection and sharing of personal reproductive or sexual health data - such as pregnancy status, contraceptive use, or abortion-related information - and gives individuals specific rights. It mandates that entities provide individuals with easy access to their data, the ability to correct inaccuracies, and the right to request deletion of such information within 15 days. The law also requires clear privacy policies detailing data practices and prohibits retaliation against individuals who exercise these rights, such as charging higher prices or denying services. It applies broadly to most businesses (excluding HIPAA-covered healthcare providers) and is enforced by the FTC with private lawsuits allowed for violations.
HR 4084, the Access to Birth Control Act, requires pharmacies that stock contraception to provide it without delay when requested by a customer. If a requested method is out of stock, pharmacies must immediately offer referrals to nearby pharmacies or expedite an order. The bill prohibits pharmacists from intimidating customers, misrepresenting availability, breaching confidentiality, or refusing to fill valid prescriptions for contraception. It directly affects pharmacies nationwide, addressing reported refusals to provide birth control - particularly after the *Dobbs* decision - and ensures access to FDA-approved contraceptive methods without cost-sharing barriers.
This bill provides federal grants to public or nonprofit health care providers serving minority, low-income, or medically underserved communities to expand maternal and infant health services. It specifically funds prenatal, postnatal, and postpartum care while requiring grantees to offer culturally appropriate services and limit administrative costs to 10% of grant funds. Priority is given to organizations led by or located within the communities they serve, aiming to reduce racial and economic disparities in care access and health outcomes. The funding is authorized for fiscal years 2026-2030, with grantees required to coordinate with other federal maternal health programs to avoid duplication.
HR 6765, the Safe Passages Act of 2025, establishes a global program to reduce maternal and child mortality in low- and lower-middle-income countries by funding life-affirming health interventions. The bill directs $400 million annually to train local providers (including midwives and community health workers) in preventing/treating leading causes of maternal death (like hemorrhage and preeclampsia), provide medical resources, support father involvement, and deliver nutrition care during the first 1,000 days of life. It explicitly prohibits funding for abortion services and requires programs to promote natural fertility awareness methods and "life-affirming care" aligned with respect for life from conception. The Act mandates annual reporting on training outcomes, facility upgrades, mortality data comparisons, and compliance with its restrictions.
HR 2469, the Abortion DOULAS Act, mandates a study by the Secretary of Health and Human Services on abortion doula care - non-clinical support provided by trained professionals before, during, and after abortions. The study will collect data from patients, doulas, and providers to assess benefits, barriers (like cost and limited Medicaid coverage), and accessibility, especially for marginalized communities. It requires a report to Congress within 18 months, including recommendations for integrating abortion doula care into state Medicaid programs. The bill directly affects patients seeking abortion care, abortion doulas, and state Medicaid systems by focusing on evidence-based policy development. It does not alter current coverage but aims to inform future policy changes.
The Veteran Families Health Services Act of 2025 expands reproductive health services for military members and veterans. It requires the Department of Defense to provide fertility preservation services, including cryopreservation of reproductive genetic material before deployment or hazardous assignments for active duty service members. The bill also mandates the Department of Veterans Affairs to provide fertility treatment, counseling, and adoption assistance to veterans and their partners without regard to sex, gender identity, or sexual orientation. The law establishes coordination between military and VA health services to ensure continuity of care during the transition from active duty to veteran status. It includes provisions allowing veterans to maintain control over stored genetic material and make decisions about its use.
S 2239, the "Improving Access to Prenatal Care for Military Families Act," allows pregnant service members and their dependents to enroll in TRICARE Select health coverage immediately upon pregnancy, treating it as a qualifying event (like a job change or separation) rather than requiring them to wait for other life events. The bill establishes a 5-year pilot program starting within 180 days of enactment, requiring the Secretary of Defense to implement this change and report annually to Congress on enrollment trends. These reports must detail enrollment changes by month and by specific circumstances, such as separation from duty or pregnancy itself. The bill directly affects military families seeking timely prenatal care under TRICARE Select, aiming to streamline access without altering existing eligibility rules.